Therapeutic target
- Early detection of possible complications (hemorrhages, shock); see under “Symptoms – complaints”/ warning signs (red flags).
Therapy recommendations
- Causal therapy is not possible.
- Close clinical and laboratory monitoring (see under laboratory diagnostics).
- Inpatient admission depending on the general condition and always in the case of a platelet drop (drop in blood platelets) to < 100,000 /μl
- Symptomatic therapy (analgesics/antipyretics).
- Caution. Do not use drugs that affect blood clotting, such as acetylsalicylic acid (ASA).
- Increase in hematocrit (volume fraction of cellular elements in the blood; erythrocytes make up the largest fraction of this at 96%) > 20% indicates significant extravascular (“outside the vessels“) plasma loss → indication for intravenous (“into the vein“) volume administration (to avoid shock syndrome; see under Shock/Pharmacotherapy).
- According to current knowledge, prophylactic administration of platelets and corticosteroids is not indicated.
- Ribavirin therapy may be considered if renal problems are present (methyltransferase, which affects 5′-cap structure, may be inhibited by ribavirin).
- See also under “Other Therapy.”